StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research report released on Wednesday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Down 4.7 %
NASDAQ:TTNP opened at $3.47 on Wednesday. Titan Pharmaceuticals has a one year low of $3.03 and a one year high of $14.80. The firm’s fifty day moving average is $3.46 and its two-hundred day moving average is $4.58.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last issued its quarterly earnings data on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) earnings per share for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Recommended Stories
- Five stocks we like better than Titan Pharmaceuticals
- Transportation Stocks Investing
- IBM’s AI Bet Pays Off—What’s Next for Investors?
- The How and Why of Investing in Gold Stocks
- 3 Reasons to Treat AMD’s Drop as an Entry Opportunity
- High Flyers: 3 Natural Gas Stocks for March 2022
- Qualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
